Serum levels of selected chemokines in systemic lupus erythematosus patients

Rheumatology International

Volumn 33, Issue 9, 2013, Pages 2423-2427

  Hrycek, Eugeniusz ^a   Franek, Andrzej ^a   Błaszczak, Edward ^a   Dworak, Justyna ^a   Hrycek, Antoni ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Associations; Chemokines; Leukocytes; SLE; Therapy

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MONOCYTE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; CHEMOKINE CCL2; CHEMOKINE CXCL10; CHEMOKINE CXCL12; CHEMOKINES; FEMALE; HUMANS; INTERLEUKIN-8; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84883202930     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2393-5     Document Type: Article

References (24)

1. Kong KO, Tan AW, Thong BYH, Lian TY, Cheng YK, Teh CL, Koh ET, Chng HH, Lau TC, Leong KR, Leung BP, Howe HS (2009) Enhanced expression of interferon-inducible protein -10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 156:134-140
2. Hrycek A, Pochopień-Kenig G, Ścieszka J (2007) Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity 40:217-222
3. Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Tekehara K, Sato S (2003) Serum concentrations of the CXC chemokines Interleukin 8 and Growth-Regulated Oncogene-α are elevated in patients with systemic sclerosis. J Rheumatol 30:1524-1528
4. Kaneko H, Ogasawara H, Naito T, Akimoto H, Hishikawa T, Lee S, Segikawa I, Tokano Y, Takasaki Y, Hirose S-I, Hashimoto H (1999) Circulating levels of β-chemokines in systemic lupus erythematosus. J Rheumatol 26:568-573
5. Wang A, Guilpain Ph, Chong BF, Chouzenoux S, Guillevin L, Du Y, Zhou XJ, Lin F, Fairhurst AM, Boudreaux Ch, Roux Ch, Wakeland EK, Davis LS, Batteux F, Mohan Ch (2010) Dysregulated expression of CXCR4/CXCL12 in subset of patients with systemic lupus erythematosus. Arthritis Rheum 62:3436-3446
6. Chong BF, Mohan Ch (2009) Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 13:1147-1153
7. Ye DQ, Hu YS, Li XP, Yang SG, Hao JH, Hung F, Zhang XJ (2005) The correlation between monocyte chemoattractant protein-1 and the arthritis of systemic lupus erythematosus among Chinese. Arch Dermatol Res 296:366-371
8. Alzawawy A, Zohary M, Ablordiny M, Eldalie M (2009) Estimation on monocyte-chemoattractant protein-1 (Mcp-1) level in patients with lupus nephritis. Intern J Rheum Dis 12:311-318
9. Lima G, Soto-Vega E, Atisha-Fregoso Y, Sánchez-Guerrero J, Vallejo M, Vargas-Alarcón G, Liorente L (2007) MCP-1, RANTES, and SDF-1 polymorphisms in Mexican patients with systemic lupus erythematosus. Human Immunol 68:980-985
10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
11. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
12. Suzuki M, Hashizume M, Yoshida H, Mihara M (2010) Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 30:309-315
13. Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, von Feldt JM (2007) Monocyte chemoattractant protein-1: plasma concentration and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 34:740-746
14. Lit LCW, Wong CK, Tam LS, Li EKM, Lam CWK (2006) Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 65:209-215
15. Bauer JW, Petri M, Batliwalla FM, Koeuth Th, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60:3098-3107
16. Robak E, Kulczycka L, Sysa-Jȩdrzejowska A, Wierzbowska A, Robak T (2007) Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 18:9-15
17. Narumi S, Takeuchi T, Kobayashi Y, Konishi K (2000) Serum levels of IFN- inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12:1561-1565
18. Szekanecz Z, Szücs G, Szántó S, Koch AE (2006) Chemokines in rheumatic diseases. Curr Drug Targets 7:91-102
19. Hsich S-C, Wu T-H, Tsai C-Y, Li K-J, Lu M-C, Wu C-H, Yu C-L (2008) Abnormal in vitro CXCR2 modulation and defective cationic ion transporter expression on polymorphonuclear neutrophils responsible for hyporesponsiveness to IL-8 stimulation in patients with active systemic lupus erythematosus. Rheumatology 47:150-157
20. Link DC (2005) Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res 32:169-178
21. Klebanoff SJ, Clark BA (1978) The neutrophil: function and clinical disorders. North-Holland, Amsterdam
22. Matamoros MC, Walker BK, Van Dyke K, Van Dyke CJ (1983) Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes. Pharmacology 27:29-39
23. Kotulová D, Stefanovic J (1983) Phagocytic capacity of human leukocytes preincubated with Imuran and prednisone. J Hyg Epidemiol Microbiol Immunol 27:253-257
24. Ferreira S, Vasconcelos J, Marinho A, Farinha F, Almeida I, Correia J, Barbosa P, Mendenca T, Vasconcelos C (2009) Linfopenia T CD4 no lúpus eritematoso sistémico. Acta Rheumatol Port 34:200-206